Therapeutic Areas: Dermatology | Oncology | Family Medicine
Melanoma Clinical Trials
A listing of Melanoma medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Birmingham : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Birmingham : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Arizona
Gilbert : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Scottsdale : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Scottsdale : Oncology Research Associates, Pllc D/B/A
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Scottsdale : Call for Information (Investigational Site 0004) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Scottsdale : Pinnacle Oncology Hematology
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Tucson : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Tucson : Arizona Clinical Research
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Tucson : University of Arizona Cancer Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Tucson : Call for Information (Investigational Site 0007)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Tucson :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Arkansas
Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Little Rock : University of Arkansas for Medical Sciences
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
California
Beverly Hills : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Beverly Hills : Beverly Hills Cancer Center
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Beverly Hills : Call for Information (Investigational Site 0027) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Beverly Hills : Call for Information (Investigational Site 0061)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Concord : Updated
A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Concord : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Duarte : City of Hope
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Encinitas : San Diego Pacific Oncology and Hematology Associates, Inc.
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Fresno : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
La Jolla : Moores UCSD Cancer Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
La Jolla :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
La Jolla : Moores UCSD Cancer Center
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
La Jolla : Moores UCSD Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
La Jolla :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Los Angeles :
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Los Angeles : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Los Angeles :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Los Angeles :
A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Los Angeles :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Los Angeles :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Los Angeles : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Los Angeles :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Los Angeles : University Of California - Los Angeles Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Los Angeles : The Angeles Clinic & Research Institute Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Los Angeles : University of California Los Angeles
Combination of Temozolomide and Sunitinib in Treatment of Patients With Metastatic and Unresectable Malignant Melanoma
Los Angeles : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Los Angeles : Research Site Updated
Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
Los Angeles : Childrens Hospital Of La
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Los Angeles : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Los Angeles : USC Norris Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Los Angeles : University of California, Los Angeles
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Los Angeles : Jonsson Comprehensive Cancer Center
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Los Angeles : The Angeles Clinic and Research Institute
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Los Angeles : The Angeles Clinic and Research Institute
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Los Angeles : Call for Information (Investigational Site 0015) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Los Angeles : Call for Information (Investigational Site 0010) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Los Angeles : Call for Information (Investigational Site 0034)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Los Angeles : Call for Information (Investigational Site 0018)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Los Angeles :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Los Angeles : Cedars Sinai Medical Center
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Orange : Children'S Hospital Of Orange County
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Orange : Chao Family Comprehensive Cancer Center
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
San Diego : UCSD Moores Cancer Center Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
San Francisco : University of San Francisco, California
A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases
San Francisco : St Mary's Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
San Francisco :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
San Francisco : San Francisco Oncology Associates Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
San Francisco : University of California, San Francisco Updated
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
San Francisco : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
San Francisco : Research Site Updated
Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
San Francisco : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
San Francisco : Northern California Melanoma Center/ St. Mary's Medical Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
San Francisco : Call for Information (Investigational Site 0008) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
San Francisco : UCSF Helen Diller Comprehensive Cancer Center
Trial of pIL-12 Electroporation Malignant Melanoma
Santa Monica : The Angeles Clinic
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Santa Monica :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Santa Monica : John Wayne Cancer Institute
Trial of pIL-12 Electroporation Malignant Melanoma
Santa Rosa : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Stanford : Stanford Cancer Center - Stanford University
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Temecula : Pacific Dermatology Institute
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Vallejo : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Colorado
Aurora :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Aurora : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Aurora : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Aurora : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Aurora : University of Colorado Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Aurora : Anschutz Cancer Pavilion
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Aurora : Call for Information (Investigational Site 0016)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Aurora :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Denver : University of Colorado, Denver
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Connecticut
New Haven : Yale University School Of Medicine Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
New Haven : Yale University School Of Medicine Updated
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
New Haven : Smilow Cancer Hospital at Yale New Haven
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
New Haven : Yale School of Medicine Updated
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
District of Columbia
Washington : The Melanoma Center at the Washington Cancer Institute
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Washington : MedStar Clinical Research Ctr at Washington Hospital Center
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Washington : Call for Information (Investigational Site 0021)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Washington : Georgetown Lombardi Comprehsnive Cancer Center
The Effects of Vemurafenib on Immunity in Patients With Melanoma
Florida
Fort Lauderdale : Holy Cross Hospital Updated
IMPULSE
DeLand : Liberty Irb, Inc
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
Fort Lauderdale : Call for Information (Investigational Site 0017)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Fort Myers : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Fort Myers :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Jacksonville : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Jacksonville : Baptist Cancer Institute
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Jacksonville : Call for Information (Investigational Site 0003) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Jacksonville : Baptist Cancer Institute Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
Lakeland : Lakeland Regional Cancer Center
Trial of pIL-12 Electroporation Malignant Melanoma
Miami Beach : Research Site
A Phase 1 Study to Evaluate MEDI4736
Miami Beach : Mount Sinai Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Miami Beach : Mount Sinai Medical Center Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Miami Beach : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Miami Beach : MSMC Research Program
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Miami Beach : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Miami Beach : Mount Sinai Medical Center Comprehensive Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Miami Beach : Mount Sinai Medical Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Miami Beach : Call for Information (Investigational Site 0053)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Orlando : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Orlando : Md Anderson Cancer Center Orlando Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Orlando : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Orlando : Md Anderson Cancer Center Orlando
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Orlando : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Orlando : MD Anderson Cancer Center-Orlando
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Ormond Beach : Ameriderm Research
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
St. Petersburg :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
St. Petersburg :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Tallahassee : Dermatology Associates of Tallahassee
Post-Approval Study of MelaFind
Tampa : Research Site
A Phase 1 Study to Evaluate MEDI4736
Tampa :
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Tampa : oH. Lee Moffitt Cancer Center/University of South Florida Moffitt SC Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Tampa : H. Lee Moffitt Cancer Center/University of South Florida Moffitt 5
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Tampa : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tampa : H. Lee Moffitt Cancer Center & Research Institute Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
Tampa : H. Lee Moffitt Cancer Center & Research Institute
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
Tampa : H. Lee Moffitt Cancer Center & Research Inst, Inc
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Tampa : Call for Information (Investigational Site 0018) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Tampa : H. Lee Moffitt Cancer Center & Research Institute Updated
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)
Tampa : H. Lee Moffitt Cancer Center
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Tampa :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
Georgia
Savannah : Memorial University Medical Center Updated
CTSU/ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High-Risk Melanoma
Atlanta : Winship Cancer Institute Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Atlanta : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Atlanta : Winship Cancer Institute
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Augusta : Research Site
A Phase 1 Study to Evaluate MEDI4736
Illinois
Elgin : Sherman Health
ECOG E1609 Phase III Randomized Study of Adjuvant Ipilimumab Versus High-Dose Recombinant Interferon Alfa-2b in Patients With High-Risk Stage IIIB, IIIC, or IV Melanoma
Chicago : Rush University Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Chicago :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Chicago : Rush University Medical Center
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Chicago : Research Site Updated
Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
Chicago : University Of Chicago Updated
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Chicago : Rush Pres St Lukes Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Chicago : Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
Chicago : University of Chicago
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Maywood : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Maywood : Loyola University Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Niles : Oncology Specialists, SC
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Niles : Oncology Specialists, SC (OSSC)
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Park Ridge :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Park Ridge : Oncology Specialists, SC
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Park Ridge :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Indiana
Goshen :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Goshen : Indiana University Health Goshen Center for Cancer Care
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Indianapolis : Investigative Clinical Research of Indiana
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Indianapolis :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Indianapolis :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Indianapolis : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Indianapolis : Indiana University Melvin and Bren Simon Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Indianapolis : Indiana University - Simon Cancer Center
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Indianapolis : Indiana University Melvin And Bren Simon Cancer Center
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Indianapolis : Investigative Clinical Research of Indiana
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Iowa
Iowa City : University of Iowa Hospitals and Clinics
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Iowa City : Research Site Updated
Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
Iowa City : University of Iowa Hospitals and Clinics
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Iowa City : University of Iowa Hospitals and Clinics
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Iowa City : Call for Information (Investigational Site 0028)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Iowa City : University of Iowa Hospitals and Clinics
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Kentucky
Lexington : Central Kentucky Research Associates
Melanoma Vaccine
Lexington : Central Kentucky Research Associates
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Lexington : Central Baptist Hospital
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Louisville :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Louisville : James Graham Brown Cancer Center
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Louisville : University Of Louisville Medical Center, Inc., Dba
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Louisville : University of Louisville Hospital
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Louisiana
Baton Rouge : The Baton Rouge Clinic, AMC
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Maryland
Baltimore : The Johns Hopkins University
Post-Approval Study of MelaFind
Baltimore : Weinberg Cancer Institution at Franklin Square
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Baltimore : Call for Information (Investigational Site 0031)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Bethesda :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Lutherville : Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins Updated
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Massachusetts
Boston : Massachusetts General Hospital Mass General 2 Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Boston : Dana Farber Cancer Institute DFCI (4)
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Boston : Massachusetts General Hospital Mass General 2
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Boston : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Boston :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Boston : Massachusetts General Hospital Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Boston : Beth Israel Deaconess Medical Center Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Boston : Dana Farber Cancer Institute Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Boston : Dana Farber Cancer Institute Updated
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Boston : Dana-Farber Cancer Institute
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Boston : Dana-Farber Cancer Institute
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Boston : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Boston : Beth Israel Deaconess Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Boston : Massachusetts Eye & Ear Infirmary
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
Boston : Dana Farber Cancer Institute DFCI - Brookline
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
Boston : Dana-Farber Cancer Institute
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Boston : Massachusetts General Hospital
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Boston : Dana-Farber Cancer Institute
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Boston : Call for Information (Investigational Site 0011) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Boston : Dana-Farber Cancer Institute Updated
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)
Boston : Dana Farber Cancer Institute Updated
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)
Boston : Massachusetts General Hospital
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Boston : Dana-Farber Cancer Institute
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Boston : Beth Israel Deaconess Medical Center
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Boston : Massachusetts General Hospital
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Rockland : Please contact the US Medical Information in
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Michigan
Ann Arbor : University Of Michigan Health System Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Ann Arbor : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Detroit : Wayne State University/Karmanos Cancer Institute Wayne St
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Detroit :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Detroit :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Detroit : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Detroit : Karmanos Cancer Institute Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Detroit : Karmanos Cancer Institute
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Detroit : Karmanos Cancer Institute
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Detroit : Barbara Ann Karmanos Cancer Institute
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Detroit : Henry Ford Medical Center
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Minnesota
Fridley : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Minneapolis : University of Minnesota Masonic Cancer Center
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Minneapolis : University of Minnesota Masonic Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Minneapolis : University of Minnesota Masonic Cancer Institute
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Rochester : Mayo Clinic
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Rochester : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Rochester : Mayo Clinic Cancer Center, Mayo Clinic Rochester
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Rochester : Call for Information (Investigational Site 0002) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Missouri
Kansas City : Center for Pharmaceutical Research
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Springfield : Mercy Medical Research Institute Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
St. Louis : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
St. Louis :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
St. Louis : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
St. Louis : Washington University School Of Medicine Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
St. Louis : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
St. Louis : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
St. Louis : Washington University in St. Louis Updated
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
St. Louis : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
St. Louis : Washington University in St. Louis
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
St. Louis : Washington University School of Medicine
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
St. Louis : St. Louis Hospital
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
St. Louis :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
St. Louis : Washington University in St. Louis
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Nebraska
Lincoln : Southeast Nebraska Hematology & Oncology Consultants, Lincol
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Omaha : Midwest Cancer Center - Legacy
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Nevada
Henderson : Comprehensive Cancer Center Of Nevada Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
Las Vegas : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Las Vegas : Comprehensive Cancer Centers of Nevada
Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers
Las Vegas : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
New Hampshire
Lebanon : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Lebanon : Dartmouth-Hitchcock Medical Center
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Lebanon : Dartmouth Hitchcock Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Lebanon : Norris Cotton Cancer Center / Dartmouth-Hitchcock Medical Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Lebanon : Dartmouth-Hitchcock Medical Center Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
New Jersey
Hackensack : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Hackensack : John Theurer Cancer Center at Hackensack University Medical Center
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Hackensack : John Theurer Cancer Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Hackensack : Call for Information (Investigational Site 0032)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Morristown : Atlantic Melanoma Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Morristown : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Morristown : Atlantic Melanoma Center
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
New Brunswick : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
New Brunswick : Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
Effects of Monoclonal Antibody GC1008 in Blood Samples From Patients With Unresectable Locally Advanced or Metastatic Kidney Cancer or Malignant Melanoma Treated on Clinical Trial NCI-06-C-0200
New Brunswick : Cancer Center of NJ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Randolph :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
New Mexico
Albuquerque : New Mexico Cancer Care Alliance
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
New York
Bronx : Saint Luke's-Roosevelt Hospital Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Bronx : Montefiore Medical Center
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Buffalo : Roswell Park Cancer Institute Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Lake Success :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
New York : Research Site
A Phase 1 Study to Evaluate MEDI4736
New York :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
New York :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
New York : Nyu Clinical Cancer Center Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
New York : Memorial Sloan Kettering Cancer Center Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
New York : Memorial Sloan Kettering Cancer Center
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
New York : Memorial Sloan Kettering Cancer Center
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
New York : New York University Langone Clinical Cancer Center
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
New York : Memorial Sloan Kettering Cancer Center Updated
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
New York : Research Site Updated
Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
New York : Memorial Sloan Kettering Cancer Ctr Updated
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
New York : Mount Sinai School Of Medicine
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
New York : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
New York : Memorial Sloan-Kettering Cancer Center
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
New York : Memorial Sloan Kettering Cancer Center MSKCC 4
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
New York : Mount Sinai School of Medicine
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
New York : New York University
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
New York :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
New York : Memorial Sloan Kettering Cancer Center
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
New York : Melanoma and Sarcoma Service / Memorial Sloan Kettering Cancer Center
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
North Carolina
Raleigh : Wake Research Associates
Melanoma Vaccine
Chapel Hill : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Chapel Hill : Lineberger Comprehensive Cancer Center, University of North Carolina
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Chapel Hill : Call for Information (Investigational Site 0029)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Charlotte : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Charlotte : Levine Cancer Institute Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Charlotte : Levine Cancer Institute
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Charlotte : Blumenthal Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Durham :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Durham : Duke University Medical Center Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Durham : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Durham : Duke University Hospital
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Durham : Duke University Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Durham : Call for Information (Investigational Site 0036)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Huntersville : Updated
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Raleigh : Wake Research Associates
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Winston-salem : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Winston-Salem : Wake Forest University Baptist Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Winston-Salem : Wake Forest University School of Medicine, Comprehensive Cancer Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Ohio
Canton : Gabrail Cancer Center Research
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Cincinnati : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Cleveland : University Hospitals Of Cleveland Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Cleveland : Case Comprehensive Cancer Center
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Cleveland : University Hospitals Of Cleveland
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Cleveland : University Hospitals Siedman Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Columbus : The Ohio State University Comprehensive Cancer Center
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Columbus : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Columbus : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Oregon
Bend : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Portland : Oregon Health & Science University OHSU 2
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Portland : Providence Oncology And Hematology Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Portland : Providence Cancer Center
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Portland : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Portland : Providence Cancer Center
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Portland : Providence Portland Medical Center Updated
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Portland : Providence Portland Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Portland : Portland Providence Medical Center
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Portland : Kaiser Permanente Northwest
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Portland : Oregon Health and Science University
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Pennsylvania
Allentown : Lehigh Valley Health Network Updated
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)
Allentown : Lehigh Valley Hospital Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
Bethlehem : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Bethlehem :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Bethlehem : Saint Luke's Hospital and Health Network
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Bethlehem : Call for Information (Investigational Site 0001)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Easton : St.Luke'S Cancer Center Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Easton : St. Luke's Hospital, Anderson Campus
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Philadelphia :
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Philadelphia : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Philadelphia :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Philadelphia : Thomas Jefferson University
Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases
Philadelphia : Thomas Jefferson University
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Safety Study of MGA271 in Refractory Cancer
Philadelphia : Kimmel Cancer Center at Thomas Jefferson Univ.
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Philadelphia : Call for Information (Investigational Site 0016) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Philadelphia : Call for Information (Investigational Site 0012)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Philadelphia : Call for Information (Investigational Site 0038)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Philadelphia : Fox Chase Cancer Center
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
Philadelphia : University Of Pennsylvania Updated
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)
Philadelphia : University of Pennsylvania
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Pittsburgh : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Pittsburgh : Upmc Cancer Pavilion Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Pittsburgh : UPMC Cancer Centers
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Pittsburgh : Hillman Cancer Center
Melanoma Molecular Profiling Analysis
Pittsburgh : UPMC Hillman Cancer Center
Pilot Study of IFN α2b for Melanoma Patients
Pittsburgh : Hillman Cancer Research Pavilion, Div. of Medical Oncology
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Pittsburgh : University of Pittsburgh
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Pittsburgh : Call for Information (Investigational Site 0013) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Pittsburgh : University of Pittsburgh Cancer Institute
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Pittsburgh :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
South Carolina
Greenville : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Tennessee
Memphis : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Memphis :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Memphis : St. Jude Children'S Research Hospital
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Nashville : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Nashville : Sarah Cannon Research Institute
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Nashville :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Nashville :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Nashville :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Nashville : Vanderbilt Univeresity Medical Center Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Nashville : Tennessee Oncology, Pllc Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Nashville : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Nashville : Research Site Updated
Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
Nashville : Vanderbilt-Ingram Cancer Ctr Updated
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
Nashville : GSK Investigational Site
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Nashville : Call for Information (Investigational Site 0033)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Nashville : Vanderbilt-Ingram Cancer Center
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Nashville :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Nashville : Vanderbilt University
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Nashville : Sarah Cannon Research Institute
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Texas
Dallas : Research Across America
Do You Have Melanoma?
Amarillo : Don and Sybil Harrington Cancer Center
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Dallas : Mary Crowley Cancer Research Centers - Medical City
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Dallas : Mary Crowley Cancer Research Centers
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Dallas : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Dallas : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Dallas : Mary Crowley Cancer Research Centers
Phase II FANG in Advanced Melanoma
Dallas : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Dallas : Mary Crowley Cancer Research Center
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Dallas : Research Across America
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Dallas : Dallas Surgical Group
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Dallas : Mary Crowley Cancer Research Center
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Dallas :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Dallas : Mary Crowley Cancer Research Center
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Houston : UT MD Anderson Cancer Center
A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma
Houston : MD Anderson Cancer Center/University of Texas MD Anderson 2
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Houston :
A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Houston :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Houston :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Houston : UT MD Andreson Cancer Center
GSK2118436 and GSK1120212
Houston : UT MD Anderson Cancer Center
High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Houston : UT MD Anderson Cancer Center
Ipilimumab for Uveal Melanoma
Houston : The University of Texas MD Anderson Cancer Center Updated
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization
Houston : The University Of Texas Md Anderson Cancer Center Updated
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Houston : University of Texas MD Anderson Cancer Center
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Houston : MD Anderson Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Houston : University of Texas M.D. Anderson Cancer Center
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Houston : University of Texas MD Anderson Cancer Center
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
Houston : Md Anderson Can Cnt
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Houston : Call for Information (Investigational Site 0012) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Houston : Call for Information (Investigational Site 0060)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Houston : UT MD Anderson Cancer Center
Study of Weekly LOC-paclitaxel Injection for Melanoma
Houston : The University of Texas MD Anderson Cancer Center
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Houston : UT MD Anderson Cancer Center
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
San Antonio : Call for Information (Investigational Site 0001) Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
San Antonio : The START Center
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
San Antonio : Cancer Therapy and Research Center
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Utah
Murray : Intermountain Medical Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Salt Lake City : Huntsman Cancer Institute
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Salt Lake City : Huntsman Cancer Institute Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Salt Lake City : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Salt Lake City : Huntsman Cancer Institute
Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks
Salt Lake City : Research Site Updated
Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
Salt Lake City : Primary Children's Medical Center
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Salt Lake City : The Huntsman Cancer Institute, University of Utah
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Salt Lake City : Huntsman Cancer Institute
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Vermont
Burlington : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Burlington : Fletcher Allen Health Care, Inc.
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Virginia
Charlottesville : University of Virginia
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
Charlottesville : University of Virginia Health System
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Charlottesville : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Charlottesville : University Of Virginia Health System Updated
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Charlottesville : University of Virginia Hospital
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Charlottesville : University of Virginia
Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
Norfolk : Clinical Research Associates of Tidewater
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Washington
Seattle : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Seattle : Seattle Cancer Care Alliance Updated
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Seattle : Seattle Cancer Care Alliance
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Seattle : Call for Information (Investigational Site 0025)
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Seattle : Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Trial of pIL-12 Electroporation Malignant Melanoma
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
ECOG 1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
Morgantown : West Virginia University - Clinical Trials Research Unit
N0879: A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma
Wisconsin
Madison : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Milwaukee : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Argentina
Buenos Aires : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Buenos Aires : Instituto Médico Alexander Fleming
Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
Caba : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Capital Federal : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Rosario : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
San Miguel de Tucumán : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Santa Fe : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Viedma : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Australia
Adelaide : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Adelaide, SA : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Albury/Wodonga : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Ashford Sa : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Auchenflower : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Box Hill : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Box Hill : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Brisbane : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Camperdown : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Camperdown : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Casuarina : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
East Melbourne : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
East Melbourne :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Frankston : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Gateshead : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Greenslopes : GSK Investigational Site
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.
Greenslopes : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Greenslopes : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Greenslopes Qld : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Heidelberg : Austin Health, LICR Melbourne Austin Branch
A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumbab Therapy in Patients With Advanced Metastatic Melanoma
Herston : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Herston :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Herston : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Herston : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Hobart : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Launceston : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Lismore : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Malvern : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Melbourne : Novartis Investigative Site Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Melbourne :
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Melbourne : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Nedlands : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
North Ryde : Merck Sharp & Dohme Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
North Ryde : Merck Sharp & Dohme
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
North Sydney : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
North Sydney : GSK Investigational Site
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.
North Sydney : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
North Sydney : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
North Sydney : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Parkville : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Perth :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Prahran : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
South Brisbane : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Southport : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Townsville :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Wendouree : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
West Heidelberg : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Westmead :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Westmead : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Westmead : Local Institution
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Westmead : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Wodonga, Vic : Updated
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Woodville :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Woodville : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Woodville South : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Woolloongabba : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Woolloongabba : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Woolloongabba : Research site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Austria
Graz : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Innsbruck :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Innsbruck : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Linz : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Linz : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Salzburg : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Salzburg : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Salzburg : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
St. Pölten : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Vienna : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Wels : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Wels :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Wien : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Wien : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Wien : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Belgium
Antwerp : Universitair Ziekenhuis Antwerpen
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Brasschaat : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Brussel : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Brussels : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Brussels : Jules Bordet Institute
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Brussels : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Brussels : Cliniques universitaires Saint-Luc, Centre du Cancer
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients
Bruxelles : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Bruxelles : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Bruxelles :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Bruxelles : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Edegem : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Edegem : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Edegem : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Gent :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Gent : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Hasselt : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Hasselt :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Jette : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Jette : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Kortrijk : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Kortrijk :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Kortrijk : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Leuven : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Leuven : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Leuven : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Leuven : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Liège : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Namur : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Roeselare : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Wilrijk : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Brazil
Belo Horizonte : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Ijui : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Porto Alegre : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Rio de Janeiro : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Salvador : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
São Paulo : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
São Paulo - SP : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Canada
Calgary : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Edmonton : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Edmonton : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Halifax : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Hamilton : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Kingston : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Kirkland : Merck Frosst Canada Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Moncton : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Montreal : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Montreal : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Montreal :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Montreal : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Montreal : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Oshawa : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Ottawa :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Ottawa : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Quebec : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Quebec :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Quebec : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Toronto : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Toronto : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Toronto :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Toronto : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Toronto : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Vancouver :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Vancouver : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Windsor : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Winnipeg :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Winnipeg : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Czech Republic
Hradec Kralove : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Hradec Kralove :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Olomouc : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Ostrava - Poruba : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Ostrava - Poruba :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Praha : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Praha :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Praha 10 : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Praha 2 : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Zlin : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Denmark
Aarhus : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Århus C : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Herlev : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Herlev : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Odense : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Odense : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Ecuador
Guayaquil : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Portoviejo : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Estonia
Tallinn :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Tartu :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Finland
Helsinki : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Jyvaskyla : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Tampere : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Turku : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
France
Avignon Cedex 2 : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Bayonne : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Bordeaux : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Bordeaux :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Bordeaux : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Bordeaux : Hôpital Saint-André
DNA Repair Inhibitor & Irradiation on Melanoma
Bordeaux : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Bordeaux : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Bordeaux : Local Institution Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
Boulogne Billancourt :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Boulogne sur Mer : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Boulogne-Billancourt : Hôpital Ambroise Paré
DNA Repair Inhibitor & Irradiation on Melanoma
Brest : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Brest Cedex : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Colmar :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Dijon : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Dijon : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Grenoble : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Grenoble : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Lille : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Lille :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Lille : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Lille : Centre Oscar Lambret
DNA Repair Inhibitor & Irradiation on Melanoma
Lille : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Lille : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Lille : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Lyon :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Lyon : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Marseille : Hôpital Sainte Marguerite
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit
Marseille : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Marseille :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Marseille : Hôpital de la Timone
DNA Repair Inhibitor & Irradiation on Melanoma
Marseille : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Marseille cedex 5 : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Marseille Cedex 5 : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Montauban : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Montivilliers : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Montpellier :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Montpellier : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Montpellier : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Montpellier : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Montpellier cedex 5 : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Nantes :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Nantes : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Nantes : Hôpital hôtel-Dieu
DNA Repair Inhibitor & Irradiation on Melanoma
Nantes : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Nantes : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Nantes : Centre Hospitalier Universitaire de Nantes
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Nantes Cedex 1 : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Nice : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Paris : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Paris :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Paris : Hôpital Saint-Louis
DNA Repair Inhibitor & Irradiation on Melanoma
Paris : Groupe Hospitalier Cochin - Hôtel Dieu-Broca
DNA Repair Inhibitor & Irradiation on Melanoma
Paris : Institut Curie
DNA Repair Inhibitor & Irradiation on Melanoma
Paris : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Paris : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Paris : MSD France Updated
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)
Paris : Local Institution Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
Paris Cedex 10 : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Pessac :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Pierre Benite : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Pierre Benite : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Pierre Benite : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Quimper : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Reims Cedex : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Rennes : Centre Eugène Marquis
cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project
Rennes : Rennes University Hospital
cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project
Rennes : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Rennes Cedex : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Rouen :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Toulouse : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Toulouse Cedex 3 : Novartis Investigative Site Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Toulouse Cedex 3 : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Vandoeuvre Les Nancy :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Villejuif : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Villejuif :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Villejuif : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Villejuif : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Villejuif Cedex : Novartis Investigative Site Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Villejuif cedex : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Germany
Aachen : Dept of Dermatology, University of Aachen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Augsburg : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Augsburg : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Berlin : Dept of Dermatology, University of Berlin Charite
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Berlin : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Bochum : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Bochum : Dept of Dermatology, University of Bochum
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Bonn : Medizinisches Zentrum Bonn Friedensplatz
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Bonn : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Bonn : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Buxtehude : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Buxtehude : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Buxtehude : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Buxtehude : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Chemnitz : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Dresden : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Düsseldorf : Research site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Erfurt : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Erfurt : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Erfurt : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Erfurt : Local Institution Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
Erlangen : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Essen : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Essen : GSK Investigational Site
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.
Essen : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Essen : Dept of Dermatology, University of Essen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Essen : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Essen : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Essen : Medizinische Fakultät der Universität Duisburg-Essen
RBL001/RBL002 Phase I Clinical Trial
Frankfurt : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Frankfurt : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Frankfurt / Main : Dept of Dermatology, University of Frankfurt
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Frankfurt am Main : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Frankfurt/Oder : Dermatology, Klinikum Frankfurt/Oder
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Freiburg : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Freiburg : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Freiburg : University Medical Center Freiburg, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Gera : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Gera : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Goettingen : Local Institution Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
Haar : Merck Sharp & Dohme GmbH
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Hamburg : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Hannover : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Hannover : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Hannover : Dept of Dermatology, University of Hannover
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Hannover : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Hannover : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Hannover : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Heidelberg : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Heidelberg : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Heidelberg : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Heilbronn : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Homburg/Saar : Dept of Dermatology, Saarland University
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Jena : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Jena : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Jena : Dept of Dermatology, University of Jena
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Kiel : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Kiel : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Kiel : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Kiel :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Kiel : Dept of Dermatology, University of Schleswig-Holstein Campus Kiel
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Kiel : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Kiel : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Kiel : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Koeln : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Koeln :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Koeln : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Koeln : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Koln : Local Institution Updated
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma
Köln : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Köln : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Köln : University Medical Center Collogne, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Leipzig : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Leipzig : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Lübeck : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Ludwigshafen : Dermatology, Klinikum Ludwishafen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Ludwigshafen : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Luebeck : Dept of Dermatology, University of Schleswig-Holstein Campus Luebeck
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Luebeck : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Magdeburg : Dept of Dermatology, Univeristy of Magdeburg
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Magdeburg : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Magdeburg : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Mainz : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Mainz :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Mainz : Dept of Dermatology, University of Mainz
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Mainz : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Mainz : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Mainz : Universtitätsmedizin der Johannes-Gutenberg Universtität
RBL001/RBL002 Phase I Clinical Trial
Manheim : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Mannheim : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Mannheim :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Mannheim : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Mannheim : Dept of Dermatology, University of Mannheim
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Mannheim : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Mannheim : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Marburg : Dept of Dermatology, University of Marburg
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Muenchen : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Muenchen : Dept of Dermatology, University of Muenchen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Muenchen : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Muenster : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Muenster :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Muenster : Dept of Dermatology, University of Muenster
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Muenster : Dept of Medical Oncology, Fachklinik Hornheide
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
München : Research site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Munich : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Münster : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Münster : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Nuernberg : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Plauen : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Quedlinburg : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Quedlinburg : Dermatology, Klinikum Dorothea Christiane Erxleben
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Regensburg : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Regensburg : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Tübingen : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Tübingen : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Tübingen : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tübingen : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Tuebingen :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Tuebingen : Dept of Dermatology, University of Tuebingen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Tuebingen : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Tuebingen : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Wiesbaden : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Wuerzburg : Dept of Dermatology, University of Wuerzburg
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Wuerzburg : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Wuerzburg : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Würzburg : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Hungary
Budapest : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Budapest : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Debrecen : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Gyula : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Kaposvár : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Miskolc : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Szeged : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Ireland
Co.Cork : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Cork : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Dublin : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Dublin : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Galway : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Tullamore : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Israel
Beer Sheva : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Haifa : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Jerusalem : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Jerusalem : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Jerusalem : Oncology institute, Shaare Zedek Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Jerusalem : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Ramat Gan : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Ramat-Gan : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Tel Aviv : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Tel Hashomer : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel Hashomer : Oncology Institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel-Aviv : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Tel-hashomer : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Italy
Bari :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Bari : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Bergamo :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Bergamo : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Genova : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Genova : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Genova :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Genova :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Genova : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Genova : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Genova : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Meldola - FC : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Milano :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Milano :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Milano : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Milano : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Milano : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Milano : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Napoli : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Napoli : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Napoli : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Napoli :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Napoli : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Napoli : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Napoli : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Padova : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Padova : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Padova : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Padova : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Pisa : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Roma : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Roma :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Roma :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Roma : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Roma : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Siena : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Siena :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Siena : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Siena : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Siena : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Japan
Chiyoda-Ku, Tokyo : MSD K.K.
A Study of Pegylated Interferon Alfa-2b as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (P08556)
Chuo-ku : Local Institution
Phase 2 Study of Ipilimumab Plus DTIC in Japanese Advanced Melanoma Patients
Korea, Republic of
Goyang-si, Gyeonggi-Do : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Seoul : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Netherlands
Amsterdam : Antoni van Leeuwenhoek Ziekenhuis
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Amsterdam : Vrije Universiteit medisch centrum (Vumc)
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Amsterdam : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Amsterdam : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Groningen : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Groningen : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Groningen : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Haarlem : Merck Sharp & Dohme BV
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Leeuwarden : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Leiden : Leids Universitair Medisch Centrum (LUMC)
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Leiden : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Leiden : Novartis Investigative Site
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Maastricht : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Maastricht : Maastricht Universitair Medisch Centrum
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Maastricht : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Rotterdam : Novartis Investigative Site
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Rotterdam : Erasmus MC
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Rotterdam : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Rotterdam : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Rotterdam : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Utrecht : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
New Zealand
Auckland : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Christchurch : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Christchurch : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Hamilton : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Hamilton : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Newtown, Wellington : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Palmerston North : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Tauranga : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Norway
Drammen : MSD Norge A/S
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Kristiansand : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Oslo : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Oslo : Novartis Investigative Site Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Oslo : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Poland
Gdansk : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Konin : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Poznan : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Poznan : WCO (Great Poland Cancer Centre)
Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma
Warszawa : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Romania
Timisoara : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Russian Federation
Chelyabinsk : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Krasnodar :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Magnitogorsk : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Moscow :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Moscow : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Nizhniy Novgorod : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Ryazan : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
St. Petersburg : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
South Africa
Durban : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Johannesburg : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Pietermaritzburg : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Pretoria : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Spain
Badalona : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Barcelona : Novartis Investigative Site Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Barcelona : Novartis Investigative Site Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Barcelona : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Barcelona : Novartis Investigative Site
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Barcelona :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Barcelona : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Barcelona : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Barcelona : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Hospitalet de Llobregat, Barcelona : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Las Palmas De Gran Canaria : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
l'Hospitalet de Llobregat : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Madrid : Novartis Investigative Site Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Madrid : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Madrid : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Madrid : Merck Sharp and Dohme de Espana S.A.
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Majadahonda : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Málaga : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Marbella :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Palma de Mallorca : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Pamplona : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Pamplona : Updated
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Pamplona : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Pamplona : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Pamplona : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Santiago de Compostela : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Sevilla : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Sevilla : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Valencia : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Valencia : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Sweden
Goteborg : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Göteborg : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Göteborg : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Jönköping : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Jönköping :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Linköping : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Lund : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Lund : Lunds Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Malmö : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Sollentuna : MSD
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Stockholm : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Stockholm : Södersjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Stockholm : Karolinska Sjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Umeå : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Umeå : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Umeå : Norrlands Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Uppsala : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Uppsala : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Växjö :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Switzerland
Baden : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Basel : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Basel : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Chur : Novartis Investigative Site Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Genève : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Lausanne : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Lausanne : Oncology Department, CHUV
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients
Lucerne 6 : MSD International GmbH
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Lugano : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Zuerich : Novartis Investigative Site Updated
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Zuerich : Novartis Investigative Site Updated
Dose Escalation Study to Investigate Safety, PK and Anti-tumor Activity of Pasireotide in Patients With Metastatic Melanoma or Merkel Cell Carcinoma
Zürich : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Zürich : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Zürich : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Zürich : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Taiwan
Taipei : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Taoyuan : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Thailand
Bangkok : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Songkla : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Turkey
Adana :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Adana : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Ankara :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Bakesir :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Bursa :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Diyarbakir :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Edirne :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Erzurum :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Gaziantep :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Isparta :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Istanbul :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Izmir :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Kayseri :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Konya :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Malatya :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Tokat :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Trabzon :
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Ukraine
Dnipropetrovsk : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
United Kingdom
Birmingham : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Birmingham : Queen Elizabeth Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Cambridge : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Cambridge : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Cambridge : Cambridge University Hospitals NHS Foundation Trust Updated
HYPAZ: Hypertension Induced by Pazopanib
Cambridge : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Cambridge : Addenbrooke's Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Chelmsford : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Edinburgh : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Edinburgh :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Glasgow : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Glasgow : The Beatson Institute
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Leeds : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Leeds : St James' Institute of Oncology
Study of a DNA Immunotherapy to Treat Melanoma
Leeds : St James Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Leicester : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
London : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
London : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
London : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
London : King's College London Guy's Hospital Campus
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
London : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
London : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
London : Novartis Investigative Site
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Manchester : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Manchester : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Manchester : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Manchester : Christie Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Newcastle Upon Tyne :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Newcastle upon Tyne : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Newcastle Upon Tyne and Wear : Newcastle Upon Tyne NHS Foundation Trust
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Nottingham : Department of Clinical Oncology, City Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Oxford :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Oxford : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Oxford : NIHR Biomedical Research Centre
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Oxfordshire : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Preston : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Southampton : Local Institution Updated
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Southampton : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Southampton : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Southampton : Research Site
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Southampton : Department of Medical Oncology, Southampton General Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Sutton : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Sutton :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Swansea : GSK Investigational Site Updated
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Truro : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Truro :
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Truro, Cornwall : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Wirral : Clatterbridge Centre for Oncology NHS Foundation Trust
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma